Carfora

Hot water makes a potato soft and weak, but makes an egg hard and strong. Be an egg

[emiliano francone @TomcatN95]

@toMMilanello

[Carfora @mt_carfora]

@TeresaMelani12 ZERO! 🤣

[Revolution Medicines @RevMedicines]

#ASCO26 reinforced what we know: RAS-targeted therapies are reshaping cancer treatment. Our Phase 3 RASolute 302 results demonstrate meaningful progress for patients. Excited about what's ahead.

[Dana-Farber @DanaFarber]

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

[Eric Topol @EricTopol]

Big progress vs cancer, folks.
The kind of event curves from randomized trials that we've not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done. #ASCO26, @ASCO

[Roberto Burioni @RobertoBurioni]

Siamo di fronte a una svolta senza precedenti nella lotta contro il cancro del pancreas, e contro il cancro in generale. I pessimisti, i criticoni, i medicucci, i divulgatori si rassegnino. E' una rivoluzione.

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO

[Federico Pio Fabrizio @FPFabrizioPhD]

Il suo nome è Daraxonrasib ed ha raggiunto un risultato storico: prolunga significativamente la sopravvivenza nel tumore pancreatico. Una pillola fondamentale da @ASCO che merita un thread 🧵

[BiotechTV @BiotechTV]

What the public needs to know about the pancreatic cancer treatment advance that has been in the news. With Dr. Mark Goldsmith - CEO of @RevMedicines, the company behind it. #ASCO26

[Lorenza Rimassa @LorenzaRimassa]

Standing ovation for RASOLUTE-302 of #daraxonrasib in second-line #PDAC at #ASCO26 plenary session. Finally a practice changing trial for patients with advanced PDAC. Now we need daraxonrasib in clinical practice soon! @ASCO

[Kelley Coffman D’Annibale MD @coffman_kelley]

This curve brought me to tears.

I treated a patient on this trial, and it took his terrible pain away completely within days, which is simply not common.

This represents decades of scientific perseverance and millions of patients who will now live longer and with less pain. 👏🏻

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[Daniele Banfi @danielebanfi83]

In questo esatto momento a Chicago stanno presentando il risultato più importante nel trattamento del tumore del pancreas degli ultimi 10 anni. Non una cura definitiva ma il primo passo verso un trattamento capace di migliorare il controllo della malattia. #ASCO26

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

🌟This is history
⭐️The most awaited abstract
👏 Standing ovation at Hall B1

💊 Daraxonrasib becomes the new standard of care for patients with previously treated metastatic #pancreatic #cancer
#ASCO26

[David S. Hong MD @DavidHongMD]

Standing ovation for the RASolute302 trial results! @UTMDAnderson @KRASKickers #ASCO26 @RevMedicines

[Carfora @mt_carfora]

Daraxonrasib as new SOC in 2L PDAC.
Acclamazione nella seduta plenaria di ASCO per i risultati dello studio di Fase 3 nel carcinoma pancreatico metastatico (2L).

[Maurizio Scaltriti @ScaltritiLab]

In 20 anni di congressi ho assistito a due standing ovation. La prima per un farmaco che ho contribuito a sviluppare. La seconda adesso.

[Brad Loncar @bradloncar]

This is a historic data release. A real advance for pancreatic cancer patients, and it shows that our industry goes after the hardest things and can win. #ASCO26

[Adam Feuerstein ✡️ @adamfeuerstein]

Incredible #ASCO26 moment.

Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD